NEW YORK, July 26 – Sensium Technologies has expanded its license to protein biochip technology from the University of Alberta and Canadian technology transfer company PENCE, Sensium said Thursday.
Sensium, the proteomics subsidiary of Aurora, Ontario-based biopharmaceutical company Helix BioPharma, will now be able to use the technology exclusively in drug discovery, as well as in other applications. The original license dates from 1996.
Known as heterodimer protein technology, the intellectual property in the license covers the capture and detection of proteins binding to a surface. Sensium is using the technology, along with separate molecular sensing technology, in protein biochips and other tools to discover and develop diagnostics and pharmaceuticals.
Helix BioPharma is the majority owner of Sensium, with outside investors holding 24 percent of its stock. Sensium’s board of directors includes Paul Russo, CEO of Genesis Microchip, and Robert Hodges, a Univerisity of Alberta Researcher and CEO of PENCE.